2 results
Approved WMOWill not start
To establish the safety profile of daratumumab when given in combination with bortezomib and dexamethasone in subjects with relapsed or refractory MM
Approved WMOCompleted
(1) To asses the influence of P-gp function at the BBB on flumazenil binding to the GABAA-receptor in pharmacoresistant patients with temporal lobe epilepsy (TLE), using PET and [11C]flumazenil as a ligand and tariquidar as P-gp blocker. (2) If we…